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Abstract
Probiotic bacteria have well-established beneficial ef-
fects in the management of diarrhoeal diseases. Newer 
evidence suggests that probiotics have the potential 
to reduce the risk of developing inflammatory bowel 
diseases and intestinal bacterial overgrowth after gut 
surgery. In liver health, the main benefits of probiotics 
might occur through preventing the production and/or 
uptake of lipopolysaccharides in the gut, and therefore 
reducing levels of low-grade inflammation. Specific 
immune stimulation by probiotics through processes 
involving dendritic cells might also be beneficial to the 
host immunological status and help prevent pathogen 
translocation. Hepatic fat metabolism also seems to be 
influenced by the presence of commensal bacteria, and 
potentially by probiotics; although the mechanisms by 
which probiotic might act on the liver are still unclear. 
However, this might be of major importance in the fu-
ture because low-grade inflammation, hepatic fat infil-
tration, and hepatitis might become more prevalent as 
a result of high fat intake and the increased prevalence 
of obesity.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Probiotics have been well defined and long used in 
human and animal health and nutrition. Many of  
the probiotic strains used today have been isolated 
from the human gut flora, and it is therefore more a 
reintroduction of  organisms rather than a novel concept. 
The beneficial effects of  probiotics and, especially, the 
clinical use of  probiotics in the management of  specific 
diarrhoeal diseases, including Rotavirus diarrhoea, 
Traveller’s diarrhoea and others are well accepted[1]. 
These effects are mainly based on colonisation resistance 
or the influence of  probiotics on microflora balance. 
When discussing probiotics, it must be remembered 
that the intestinal microflora, resident in the large 
intestine, will always outnumber the probiotics that can 
be administered. Furthermore, probiotic processes will 
always be confounded by the diversity of  the human 
microbiota and its variability in the face of  varied human 
diets and genetic backgrounds[2].
Within the human gut, we have to separate pro-
cesses occurring in the distal small intestine from those 
happening in the colon. The small intestine harbours 
relatively low numbers of  resident intestinal bacteria, 
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but at the same time contains the major part of  the gut 
associated lymphoid tissue (GALT), which samples in-
testinal microbes[3]. Hence modulation of  systemic im-
mune and allergic phenomena might be primarily medi-
ated by the GALT of  the small bowel. Supplementing 
qualitatively and quantitatively optimised microbes to 
this part of  the gut might stimulate Treg cell develop-
ment and consequent immunomodulation[1]. Within the 
large intestine, bacterial intervention might cause mod-
ulation of  the microbial fermentation activity and direct 
action on the colonic epithelium to alter (suppress) 
innate immunity. These processes might explain the 
impact of  probiotics on inflammatory and functional 
bowel disorders.
The research field of  probiotics is very heavily re-
viewed, using different clinical and microbiological 
angles to elucidate the topic. The aim of  this review is to 
summarise the most recent trends in probiotic research, 
focusing on the clinical use of  probiotics and their ef-
fects on the healthy and diseased gut and liver.
The direct and indirect actions of  probiotics on intes-
tinal cells and their consequences on liver (summarised 
in Figure 1) will be discussed in this review.
GUT HEALTH
Probiotics and intestinal barrier function
The intestinal barrier is seen as the first line of  defence 
against pathogens and food allergens entering the intes-
tinal tract, and probiotics have been intensely studied for 
their involvement in maintaining this barrier. In colonic 
epithelia, probiotics are suggested to stimulate mucin 
production, and therefore enhance the self  protecting 
properties of  the intestinal epithelium[4]. Furthermore, 
tight junctional proteins, important for the physical 
tightness of  the epithelial cell layer, are found to be 
enhanced by probiotics[5,6] and the disruption of  tight 
junctions by pathogens can be counteracted[7]. Besides 
these effects on the physical barrier function, evidence 
is mounting that both commensal microflora and spe-
cific probiotic supplementations specifically enhance the 
immunological barrier function of  the small intestinal 
mucosa[8]. For this cross talk between bacteria and the 
immune system, bacteria derived products including 
metabolites, cell wall components and DNA, can be 
sensed by enterocytes and immune competent cells[9]. 
Commensals, unlike pathogens, are efficiently killed by 
intestinal macrophages, therefore avoiding an inflam-
matory response in the mucosa[10]. At the same time, 
dendritic cells can sample commensals, incorporate 
them, and transport them to mensenteric lymph nodes. 
Here, commensal-loaded dendritic cells induce a local 
immune response with the activation of  specific B-cells 
to produce secretory IgA against these commensals[8,10]. 
This appears to be a paradox, but this specific and local 
immune stimulation by commensals and probiotics can 
actually be considered non-inflammatory in the mucosal 
environment and the host systemics[8]. Therefore GALT, 
and specifically the mesenteric lymph nodes, can be con-
sidered another layer of  intestinal barrier function[3,10].
Probiotics and inflammatory bowel diseases (IBD)
The pathogenesis of  IBD [ulcerative colitis (UC) and 
Crohn’s disease] remains unknown, but the intestinal 
microflora appears to play an important role. Changes 
in microflora composition have been observed in UC 
patients, with increased pro-inflammatory bacteria, in-
cluding Enterobacteriaceae, increased Bacteroides fragilis 
within the mucosal microflora[11], and decreased protec-
tive bacteria, including lactobacilli and bifidobacteria[12]. 
Probiotic treatment has the potential to decrease the 
severity of  symptoms in IBD via interaction with gut 
epithelium[13]. Proposed mechanisms include changes 
in short chain fatty acids (SCFA) production patterns, 
reduction in pro-inflammatory cytokine secretion, im-
proving Th1/Th2 ratios, and eliminating pathogens. For 
example, the production of  reuterin has been shown in 
vitro to reduce growth of  pathogens, including Escherichia 
coli (E. coli), Salmonella enterica, Shigella sonnei, and Vibrio 
cholera. Adhesion of  probiotics to enterocytes and en-
hancement of  barrier function (secretion of  B-defensins 
and mucus, TJ proteins) have also been shown for spe-
cific strains in vitro. However, it is unclear whether this 
strengthening of  the intestinal barrier function would 
also occur in the large intestine, the area most affected 
by intestinal disease. Some evidence from a mouse mod-
el of  colitis [interleukin (IL)-10 deficient mice] suggests 
that probiotic lactobacilli and the VSL#3 mix reduced 
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Figure 1  Potential mechanisms of action by which probiotics can promote 
GI health and the consequences for the liver. Probiotics and surface-layer 
proteins competitively exclude microbial pathogens from mucosal surfaces. 
Tight junction proteins, such as zona occludins-1 and claudin1, remain intact 
and thereby prevent both uptake of intact macromolecules and translocation of 
viable organisms (BT) to mesenteric lymph nodes, and ultimately to the liver. 
Through a cascade of signalling events, probiotics enhance production and 
secretion of anti-inflammatory cytokines, including interleukin-10 and transform-
ing growth factor-β, by a subset of immune cells, referred to as T regulatory 
cells. Innate immune responses to probiotics include increased mucin and 
trefoil factor production by goblet cells and enhanced production of antibacterial 
defensins by Paneth cells and intestinal epithelia.  Probiotics might alter the in-
testinal microbiota and hence limit intestinal bacteria overgrowth (IBO) and the 
production of lipopolysaccharides (LPS).
bacterial translocation (BT) and intestinal permeability in 
the colon[14,15]. Mechanistic effects can also be observed 
with non-viable probiotics and culture supernatants in vi-
tro and in animals, which might be a safer therapeutic for 
patients with impaired intestinal barrier and increased 
risk of  sepsis. Bacteria-free culture supernatant from 
Lactobacillus plantarum was shown to inhibit inflammatory 
pathways important for intestinal inflammation, such 
as nuclear factor (NF)-κB binding activity and protea-
some activity, in a young adult mouse colon cell line and 
in macrophages[16]. This might provide a novel and safe 
strategy for treatment of  IBD, if  results can be repeated 
in vivo.
Probiotics and irritable bowel syndrome (IBS)
IBS includes a range of  symptoms, such as abdominal 
pain, altered bowel habits, bloating and flatulence in 
the absence of  structural abnormalities in the intestine. 
As no curative treatment is available for IBS, therapy is 
palliative and supportive, targeting special symptoms, 
and is notoriously unsatisfactory. Studies have observed 
alterations in intestinal microflora in patients and 
increased symptoms following enteric infections, therefore 
probiotics might be a useful tool to improve symptoms. A 
meta analysis of  probiotic treatment and IBS[17] included 
20 trials with 23 probiotic treatments. This study showed 
that probiotics were associated with improved global IBS 
symptoms [risk ratio (RR) = 0.77] and with decreased 
abdominal pain (RR = 0.78). Due to the large variety 
in probiotic strains used, no analysis on strain type was 
possible. Probiotics used included B. infantis, lactobacilli 
(L. acidophilus, L. plantarum, L. reuteri, L. rhamosus), 
Saccharomyces boulardii, Streptococcus faecium, VSL#3 (mix 
of  eight), and other mixes. In a recent systematic review, 
Brenner et al[18] claimed that 16 randomized controlled 
human trials met their inclusion criteria, of  which 11 
had suboptimal study design. They concluded that only 
one study using a specific strain of  B. infantis 35 624 
efficiently improved IBS symptoms. Probiotics might 
offer a treatment possibility for IBS symptoms, but more 
controlled studies are needed to identify the ideal strain, 
dose, and duration of  treatment.
Probiotics after gut surgery
Morbidly obese patients can undergo Roux-en Y gastric 
bypass surgery (one type of  bariatric surgery) for effec-
tive and enduring weight loss. This procedure uses re-
striction in stomach size and intestinal malabsorption as 
measures for achieving substantial weight loss. Problems 
that occur postoperationally are alteration of  microflora 
with bacterial overgrowth (BO) in the blind sac of  the 
intestine, intestinal pain, and possibly impaired vitamin 
B12 status (due to lack of  intrinsic factor production 
from the stomach). This study[19] used probiotic treat-
ment (6 mo, commercial product of  unspecified lactoba-
cilli) in 44 post operational patients. BO (measured with 
hydrogen breath test) improved only after 6 mo, but 
not earlier. Vitamin B12 status improved, gastrointestinal 
symptoms remained unchanged, but post operational 
weight loss was significantly increased in the probiotic 
group. The authors speculated that increased weight loss 
might be due to changes in microflora towards extract-
ing fewer calories from the diet, although this was not 
studied. 
Probiotics/symbiotics have also been used to prevent 
postoperative infections in patients undergoing abdominal 
surgery (biliary cancer, liver transplantation, and pancreati-
coduodenectomy). Major infections were pneumonia, uri-
nary tract infection, wound infection, intra-abdominal ab-
scess, and cholangitis. A recent meta analysis[20] found that 
probiotics reduced overall infections [odds ratio (OR) = 
0.26], length of  antibiotic treatment need (OR = -4.01), 
reduced length of  postoperative hospital stays (OR = 
-2.7), but did not change overall mortality (OR = 0.98). 
Overall the use of  probiotics is very promising, although 
data are very variable (type of  surgery, type of  infection, 
and type of  probiotic treatment). However, bacteremia 
might be a potential hazard in these vulnerable patients. 
The appropriate therapeutic route, length of  therapy, time 
of  administration, dosage, and kind of  probiotic remain 
controversial and no uniform preventative strategy can be 
suggested on based of  the current literature.
LIVER HEALTH
There is a longstanding practice of  using lactulose in the 
treatment of  hepatic encephalopathy, which suggests 
involvement of  gut microflora in the management of  
chronic liver disease. Loguercio et al[21] use the phrase 
“gut liver axis” and suggest that the microflora might 
affect the liver and be cofactor in aetiology of  chronic 
liver damage. This could happen via modulating chronic 
damage by ethanol or by contributing to complica-
tions such as encephalopathy (production of  ammonia, 
ethanol, acetaldehyde, phenols, endotoxin, and benzo-
diazepines)[21]. Probiotic actions most relevant to liver 
disease are modification of  intestinal barrier function 
and prevention of  BT. Gram-negative BO, increased 
permeability, and impaired immunity all contribute to 
increased BT, and there is a strong correlation between 
the rate of  BT and the severity of  cirrhosis. Probiotics 
might alter gut flora towards protective organisms and 
increase barrier function[22].
Probiotics and non alcoholic fatty liver disease (NAFLD)
NAFLD is the most common form of  liver disease 
in the US; its incidence is rising together with rising 
problems of  obesity and Type Ⅱ diabetes. NAFLD 
includes a spectrum of  pathologies. Steatosis (fatty liver), 
is clinically asymptomatic, but might predispose the liver 
to other insults, such as lipopolysaccharides (LPS) or 
hepatotoxins, that might lead to cirrhosis. Non-alcoholic 
steatohepatitis (NASH) is an intermediate state where 
lobular inflammation occurs. Cirrhosis is the most severe 
form, responsible for most liver specific morbidity and 
mortality[23].
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Histopathological changes are very similar to alco-
holic liver disease, and there might be a common pathway 
of  development. Data suggest a “multi hit” hypothesis, 
where initial hits such as obesity and sub-clinical insulin 
resistance might promote the development of  steatosis[23]. 
This enhances the fatty liver’s vulnerability to subsequent 
insult (e.g. ethanol and LPS) that increase the produc-
tion of  pro-inflammatory cytokines [e.g. tumor necrosis 
factor (TNF)-α]. This aggravates insulin resistance and 
leads to oxidative stress (increased production of  reactive 
oxygen by hepatocytes and liver macrophages) and or-
ganelle dysfunctions, which kill hepatocytes and promote 
accumulation of  inflammatory cells in the liver and the 
development of  NASH[24]. Following years of  chronic 
inflammation this might develop into fibrogenic response 
and cirrhosis.
The contribution of  microflora in the development of  
NAFLD is mainly based on increased hepatic oxidative 
stress by increased production of  ethanol and LPS in the 
intestinal lumen, and subsequent release of  inflammatory 
cytokines in intestinal epithelia and liver macrophages. 
Both processes then lead to injury of  the intestinal 
epithelium and disrupted intestinal barrier function, which 
in turn increases hepatic exposure to intestine-derived 
toxins. This hypothesis is further supported by evidence 
that intestinal BO exacerbates fatty liver disease in 
rodents and humans, and that obese patients with NASH 
have increased prevalence of  BO. Furthermore, obese 
subjects are known to have decreased intestinal motility 
and are therefore more prone to BO. A recent clinical 
trial confirms that patients with NASH have increased 
intestinal permeability and small intestinal BO[25].
From this data, an obvious way to control the devel-
opment of  NAFLD seems to be a manipulation of  the 
gut microflora, mainly by the reduction of  BO. This can 
be achieved by antibiotic treatment, which has been used 
successfully, but is controversial due to its unspecific im-
pairment of  all microflora and its severe side effects[23]. 
Probiotic therapy, on the other hand, has been suggested 
to counteract the development of  NAFLD on various 
different levels. Competitive inhibition of  pathogens by 
probiotics might alter their inflammatory effects in intes-
tinal BO, which is associated with NAFLD. Furthermore, 
improved intestinal epithelium function and decreased 
BT and endotoxemia following probiotic treatment have 
been observed in experimental animals and humans[26]. 
In a series of  feeding studies in mice, Cani et al[27] claimed 
that high-fat feeding changes the intestinal microflora 
composition (less bifidobacteria), which led to increased 
LPS levels in plasma, pro-inflammatory cytokines and 
increased intestinal permeability. All these effects could be 
counteracted by prebiotic treatment and increasing bifido-
bacteria species (summarized in[27]). This would indicate a 
direct effect of  intestinal bacteria on low-grade inflamma-
tion, insulin insensitivity, and fat deposition in the liver.
Other research suggests a direct decrease in pro-in-
flammatory cytokines e.g. TNF-α via downregulation of  
NF-κB activity by probiotic treatments[14,28-30]. In a study 
in ob/ob mice, probiotics (VSL#3) and TNF-α anti-
bodies were used to treat NAFLD. Both treatments im-
proved liver function, reduced hepatic fatty acid content, 
and both interfered with NF-κB signalling and reduced 
hepatic fatty acid β-oxidation close to levels in lean mice. 
The authors suggest that this effect might result from 
improved hepatic insulin resistance[28]. Another study, 
using the same probiotic in normal mice, measured he-
patic natural killer T (NKT)-cell depletion in high-fat 
fed animals[31]. NKT are unconventional T cells that ex-
press both T cell and Killer cell receptors. They regulate 
hepatic inflammatory process by balancing production 
of  pro- and anti-inflammatory cytokines. Alterations of  
NKT function might lead to overproduction of  TNF-α, 
causing inflammation in insulin resistance. High-fat diet 
induced the depletion of  NKT from the liver, leading to 
insulin resistance and steatosis. Probiotics significantly 
improved all these symptoms and the effect resulted 
from TNF-α signalling and led to improved insulin 
signalling[31]. There is some suggestive evidence that pro-
biotics might have efficacy in NAFLD in humans, but 
more controlled trials are needed[30]. 
Probiotics and alcoholic liver disease
In alcoholic liver disease, bowel liver interactions are 
well described, and relationships include increased gut 
permeability, endotoxemia, and TNF-α production[32]. 
In rats, Lactobacillus GG has been shown to reduce al-
cohol induced gut leakiness and steatohepatitis[33]. The 
same group also found that the mucosa associated mi-
croflora were altered in rats on a high alcohol feed, and 
this dysbiosis could be counteracted by Lactobacillus GG 
or oat supplementation[34]. Furthermore, alcoholics have 
altered microflora with decreased numbers of  bifidobac-
teria and lactobacilli. A recent pilot study[32] compared 
control subjects with alcoholics in a clinic, either on 
standard treatment for alcoholic disease (Vitamin B1 & 
B6 supplements and diazepam, n = 34) or on standard 
treatment + probiotics (0.9 × 10e8 CFU B. bifidum and 
0.9 × 10e9 CFU L. plantarum, n = 32) for five consecu-
tive days. No placebo was included in the control group. 
They found that lactobacilli, bifidobacteria, and entero-
cocci were reduced in alcoholics and the numbers were 
restored in the probiotic treatment group. E. coli levels 
were not altered. Liver function parameters [alanine 
aminotransferase (ALT) and aspartate aminotransferase] 
were significantly improved by probiotics compared to 
standard treatment, but remained below levels found in 
healthy controls. Other liver enzymes (GGT and LDH) 
were not significantly altered. In the subgroup of  alco-
holics with well-defined hepatitis, standard treatment 
only altered total bilirubin, but probiotics improved all 
the liver parameters mentioned above. The authors con-
cluded that bifidobacteria seemed to play an important 
role in steatohepatitis of  alcoholic and non alcoholic 
causes, including obesity[35]. In a double blind placebo 
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controlled (sucrose capsule) intervention Lata et al[36] 
studied the effect of  probiotic E. coli Nissle in cirrhotic 
patients (n = 39, 34 with alcoholic cirrhosis). They 
found an improvement of  intestinal colonization in 
faeces, and a restoration of  “physiological microflora” 
in faeces (more patients with normal microflora contain-
ing lactobacilli and bifidobacteria, less patients with po-
tentially pathogenic bacteria). They also showed trends 
towards a reduced endotoxin level in blood (P = 0.07) 
and a reduced Child-Pugh score (P = 0.07), which is a 
measure for severity of  overall liver disease. Improved 
liver function by probiotics has already been published[5], 
but the mechanism remains unclear. They assume that 
microflora reduce the toxic load of  liver, e.g. reduced 
endotoxin, which stimulates pro-inflammatory cytokines 
(TNF-α, IL-1, 6)[22].
Probiotics to cure/alleviate cirrhosis?
In cir rhosis there are many conditions that alter 
microflora and the function of  the intestinal epithelium, 
as recently reviewed in detail[37]. BT is caused by BO, 
increased permeability, and altered host defence. BT and 
microflora imbalance are strongly correlated with the 
severity of  cirrhosis[38]. In a rat model of  acute liver injury 
(using either D-galactosamine or endotoxin), probiotic 
lactobacilli and bifidobacteria attenuated liver injury 
(ALT and bilirubin), reduced BT, and normalized hepatic 
TNF-α and glutathione levels compared to liver injury 
controls[39,40].
Lactobacilli might counteract BT by (1) promoting 
growth of  anaerobes and Gram-positive bacteria while 
inhibiting gram-negative bacteria, or (2) increasing 
SCFA while decreasing pH, inducing growth factors and 
proliferation of  microflora, and inhibiting adherence 
and invasion of  pathogens. Patients with liver cirrhosis 
have imbalanced intestinal microflora with increased 
aerobes (enterobacter and enterococci) and anaerobes 
(clostridia), and decreased bifidobacteria counts in stool. 
In a probiotic intervention trial in cirrhotic patients[38] 
(mainly caused by hepatitis virus B and C; HBV and 
HCV) patients received two different probiotic capsules 
[bifidobacteria + L. acidophilus + Enterococcus or Bacillus 
subtilis (B. subtilis) + Enterococcus faecium (E. faecium)], two 
capsules per day for 14 d. In both probiotic groups, 
bifidobacteria counts increased with treatment, while 
faecal pH and ammonia levels in faeces and blood 
decreased. Additionally, B. subtilis + E. faecium decreased 
clostridia counts and endotoxin levels in the blood of  
cirrhotic patients.
Flora imbalance in cirrhotics might be caused by 
decreased gut motility, diminished excretion of  sectretory 
IgA, lysozyme, mucus, acids, increased pH, shortage of  
bile acids, and excessive alcohol intake. Elevated blood 
ammonia is a crucial factor in hepatic encephalopathy 
aetiology.
Loguercio et al[21] conducted a pilot study in patients 
suffering from hepatitis of  various causes (HCV, alco-
holism, and NASH). The patients received a probiotic 
mix (Lactobacillus acidophilus, L. bifidus, L. rhamnosus, 
L. plantarum, L. salivarius, L. bulgaricus, L. lactis, L. casei, 
L. breve + fructo-oligosaccharides + vitamins). Interest-
ingly, the authors reported no effect of  probiotics in 
HCV patients. In NASH patients some liver function 
parameters (ALT and γ-glutamyltransferase) improved, 
TNF-α decreased and plasma malondialdehyde de-
creased in some patients with probiotic treatment. The 
strongest effect of  protiotics was seen in patients with 
alcoholic liver cirrhosis, where all parameters of  liver 
function improved, as did TNF-α and malondialdehyde.
From these studies in humans, it appears that the 
microflora is an important cofactor in the aetiology of  
chronic liver disease, and that probiotics might have a 
therapeutic role.
Probiotics to bind toxins and carcinogens
Some experimental evidence suggests that probiotics 
could be used to bind and immobilise toxic compounds 
within the gut lumen. Through this process, the negative 
effects of  dietary toxins could be reduced and gut and 
liver health improved. In vitro, L. rhamnosus GG is able 
to bind mycotoxins known to interfere with intestinal 
mucosal barrier. In Caco-2 cells, the negative effects 
of  mycotoxins on cell differentiation and intestinal 
integrity can be attenuated with L. rhamnosus GG[41,42]. 
In rats, genotoxic effects of  food carcinogens, such as 
heterocyclic amines, on the colonocytes and hepatocytes 
were counteracted by the use of  different probiotics[43,44]. 
Probiotics have also been shown to attenuate hepatotoxic 
effects of  aflatoxin, a well known liver carcinogen, in 
rats[45] and to reduce biomarkers of  liver cancer risk in a 
human intervention trial[46]. 
Safety considerations of probiotics
Generally recognized as safe (GRAS) status is defined 
by the Food and Drug Administration for food adjuncts 
that might not meet the usual requirements for safety 
assessment but have been used extensively without de-
monstrable harm. Probiotics are claimed to be GRAS as 
they comprise organisms identical to those in human gut 
and vaginal flora, although strain dependence needs to 
be considered and GRAS should only be granted to one 
specific probiotic preparation used in one specific food 
product[47]. Previous probiotic studies stress the safety 
of  probiotic preparations and their ability to reduce 
BT of  pathogenic bacteria to host organs and tissues. 
Probiotic BT from the intestine is difficult to induce in 
healthy animals, and therefore hard to study. From ani-
mal studies, NOAEL (no observed adverse effect levels) 
can be determined and ADI (acceptable daily intake) 
extrapolated for humans. These calculations suggest 
that up to 1014 cfu/d of  lactobacilli and bifidobacteria, 
a dose way beyond the usual intake of  109-1011 cfu/d, 
are acceptable for human consumption. In healthy hu-
mans, probiotic BT occurs occasionally. but detrimental 
effects are rare. Salminen et al[48] assessed the frequency 
of  lactobacillus bacteraemia in the Finnish population 
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following the increased consumption of  probiotic prod-
ucts in the years 1995-2000 and found no trends towards 
increased lactobacillus bacteraemia over this period. A 
recent meta analysis summarised the safety of  probiotics 
in pregnancy and concluded no effect of  lactobacillus 
and bifidobacterium species on incidence of  caesarean 
section, birth weight, or gestational age[49]. In immu-
nocompromised individuals however, this might be 
different. Cannon et al[50] summarised over 200 clinical 
cases of  lactobacillus infections and found association 
with endocarditis and bacteraemia. L. casei and rhamnosus 
were most common, and the overall mortality rate was 
nearly 30%. They also reported that the main underly-
ing conditions were cancer, diabetes, antibiotic therapy, 
organ transplantation, and abscesses. Salminen et al[51] 
investigated the severity and outcome of  lactobacillus 
bacteraemia in 89 patients, and report mortality of  26% 
1 mo after illness onset, but only in patients with severe 
underlying comorbidities. 
Future of probiotic research
Most recent developments in probiotic and prebiotic 
research use a new systems biology approach to assess 
the complex relationship between the microflora, pro-
biotic modulations, and the impact on host metabolism 
in multiple compartments. A major finding is the impact 
of  microflora modulation on host energy metabolism, 
especially lipid metabolism in the liver where marked de-
creases in plasma lipoproteins and hepatic glutamine and 
glycogen levels are observed[52]. This group uses a germ 
free mouse model colonized with human baby flora, to 
study the effects of  a probiotic intervention (L. paracasei 
or L. rhamnosus) on gut flora composition, SCFA in cae-
cal content, plasma, urine, faecal and liver metabolomics, 
and bile acids in ileal flushes.
The integration of  multicompartment metabolic data 
using hierarchical principal component analysis showed 
that probiotic lactobacilli induce changes in hepatic influx 
and efflux of  fatty acids, increased enterohepatic recycling 
of  bile acids and dietary fats, lowered plasma LP, and 
stimulated glycolysis. Probiotic intervention also changed 
the proteolytic activity and bacterial metabolism of  AA 
and SCFA in the gut[53]. In a mouse model of  high-fat 
feeding and NAFLD, an association was shown between 
the metabolism of  choline by microbiota and the host. 
The author suggested a contribution of  microflora to the 
development of  the NAFLD phenotype[54]. This complex 
analytical and statistical methodology allows investigation 
of  the impact of  microflora and probiotics on various 
body compartments simultaneously and might, in the 
future, lead to a better understanding of  the influence of  
probiotics on the host. Similarly, the complex metabolic 
relationships between the microflora and the host have 
also been studied in human cohorts and this approach 
might be used to gain further understanding of  the 
relation between changes in the microflora (dysbiosis) 
and disease[55].
CONCLUSION
It appears that specific clinical applications of  probiotics 
are safe, effective, and can clearly be recommended. 
However, the importance of  probiotic food items in 
the “maintenance of  health” in healthy individuals as 
marketed by food industries remains questionable. To 
date, no generalisation can be made from health effects 
of  one probiotic strain to another one and this remains 
a serious problem within the probiotic research field and 
its applications. Multi-dimensional research approaches, 
studying the microflora composition, its metabolic 
profile, and the impact on host metabolism appear a 
promising way forward to further describe and explore 
these complex relationships within the microflora-host 
“superorganism”.
REFERENCES
1 Ouwehand AC. Antiallergic effects of probiotics. J Nutr 
2007; 137: 794S-797S
2 Neish AS. Microbes in gastrointestinal health and disease. 
Gastroenterology 2009; 136: 65-80
3 Cummings JH, Antoine JM, Azpiroz F, Bourdet-Sicard 
R, Brandtzaeg P, Calder PC, Gibson GR, Guarner F, 
Isolauri E, Pannemans D, Shortt C, Tuijtelaars S, Watzl B. 
PASSCLAIM--gut health and immunity. Eur J Nutr 2004; 43 
Suppl 2: II118-II173
4 Caballero-Franco C, Keller K, De Simone C, Chadee K. The 
VSL#3 probiotic formula induces mucin gene expression 
and secretion in colonic epithelial cells. Am J Physiol 
Gastrointest Liver Physiol 2007; 292: G315-G322
5 Otte JM, Podolsky DK. Functional modulation of enterocytes 
by gram-positive and gram-negative microorganisms. Am J 
Physiol Gastrointest Liver Physiol 2004; 286: G613-G626
6 Commane DM, Shortt CT, Silvi S, Cresci A, Hughes RM, 
Rowland IR. Effects of fermentation products of pro- and 
prebiotics on trans-epithelial electrical resistance in an in 
vitro model of the colon. Nutr Cancer 2005; 51: 102-109
7 Johnson-Henry KC, Donato KA, Shen-Tu G, Gordanpour M, 
Sherman PM. Lactobacillus rhamnosus strain GG prevents 
enterohemorrhagic Escherichia coli O157:H7-induced 
changes in epithelial barrier function. Infect Immun 2008; 76: 
1340-1348
8 Isolauri E, Salminen S. Probiotics, gut inflammation and 
barrier function. Gastroenterol Clin North Am 2005; 34: 
437-450, viii
9 Corthésy B, Gaskins HR, Mercenier A. Cross-talk between 
probiotic bacteria and the host immune system. J Nutr 2007; 
137: 781S-790S
10 Macpherson AJ, Uhr T. Induction of protective IgA by 
intestinal dendritic cells carrying commensal bacteria. 
Science 2004; 303: 1662-1665
11 Wang M, Molin G, Ahrné S, Adawi D, Jeppsson B. High 
proportions of proinflammatory bacteria on the colonic 
mucosa in a young patient with ulcerative colitis as revealed 
by cloning and sequencing of 16S rRNA genes. Dig Dis Sci 
2007; 52: 620-627
12 Cummings JH, Macfarlane GT, Macfarlane S. Intestinal 
bacteria and ulcerative colitis. Curr Issues Intest Microbiol 
2003; 4: 9-20
13 Prisciandaro L, Geier M, Butler R, Cummins A, Howarth 
G. Probiotics and their derivatives as treatments for 
inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 
1906-1914
408 January 28, 2010|Volume 16|Issue 4|WJG|www.wjgnet.com
Gratz SW et al . Probiotics and liver diseases
409 January 28, 2010|Volume 16|Issue 4|WJG|www.wjgnet.com
14 Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, 
Yachimec C, Doyle J, Jewell L, De Simone C. Probiotic 
bacteria enhance murine and human intestinal epithelial 
barrier function. Gastroenterology 2001; 121: 580-591
15 Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak 
RN. Lactobacillus species prevents colitis in interleukin 10 
gene-deficient mice. Gastroenterology 1999; 116: 1107-1114
16 Petrof EO, Claud EC, Sun J, Abramova T, Guo Y, Waypa 
TS, He SM, Nakagawa Y, Chang EB. Bacteria-free solution 
derived from Lactobacillus plantarum inhibits multiple 
NF-kappaB pathways and inhibits proteasome function. 
Inflamm Bowel Dis 2009; 15: 1537-1547
17 McFarland LV, Dublin S. Meta-analysis of probiotics for the 
treatment of irritable bowel syndrome. World J Gastroenterol 
2008; 14: 2650-2661
18 Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The 
utility of probiotics in the treatment of irritable bowel 
syndrome: a systematic review. Am J Gastroenterol 2009; 104: 
1033-1049; quiz 1050
19 Woodard GA , Encarnacion B, Downey JR, Peraza J, 
Chong K, Hernandez-Boussard T, Morton JM. Probiotics 
improve outcomes after Roux-en-Y gastric bypass surgery: 
a prospective randomized trial. J Gastrointest Surg 2009; 13: 
1198-1204
20 Pitsouni E, Alexiou V, Saridakis V, Peppas G, Falagas ME. 
Does the use of probiotics/synbiotics prevent postoperative 
infections in patients undergoing abdominal surgery? A 
meta-analysis of randomized controlled trials. Eur J Clin 
Pharmacol 2009; 65: 561-570
21 Loguercio C, De Simone T, Federico A, Terracciano F, Tuccillo 
C, Di Chicco M, Cartenì M. Gut-liver axis: a new point of 
attack to treat chronic liver damage? Am J Gastroenterol 2002; 
97: 2144-2146
22 Sheth AA, Garcia-Tsao G. Probiotics and liver disease. J Clin 
Gastroenterol 2008; 42 Suppl 2: S80-S84
23 Solga SF, Diehl AM. Non-alcoholic fatty liver disease: 
lumen-liver interactions and possible role for probiotics. J 
Hepatol 2003; 38: 681-687
24 Medina J, Fernández-Salazar LI, García-Buey L, Moreno-
Otero R. Approach to the pathogenesis and treatment of 
nonalcoholic steatohepatitis. Diabetes Care 2004; 27: 2057-2066
25 Miele L, Valenza V, La Torre G, Montalto M, Cammarota 
G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti 
G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco 
A. Increased intestinal permeability and tight junction 
alterations in nonalcoholic fatty liver disease. Hepatology 
2009; 49: 1877-1887
26 Eizaguirre I, Urkia NG, Asensio AB, Zubillaga I, Zubillaga 
P, Vidales C, Garcia-Arenzana JM, Aldazabal P. Probiotic 
supplementation reduces the risk of bacterial translocation 
in experimental short bowel syndrome. J Pediatr Surg 2002; 
37: 699-702
27 Cani PD, Delzenne NM. The role of the gut microbiota in 
energy metabolism and metabolic disease. Curr Pharm Des 
2009; 15: 1546-1558
28 Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, 
Desimone C, Song XY, Diehl AM. Probiotics and antibodies 
to TNF inhibit inflammatory activity and improve 
nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350
29 Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro 
P, Canani RB, Calignano A, Raso GM, Meli R. Probiotics 
reduce the inflammatory response induced by a high-fat diet 
in the liver of young rats. J Nutr 2009; 139: 905-911
30 Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics 
for non-alcoholic fatty liver disease and/or steatohepatitis. 
Cochrane Database Syst Rev 2007; CD005165
31 Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced 
hepatic steatosis and insulin resistance by increasing hepatic 
NKT cells. J Hepatol 2008; 49: 821-830
32 Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, 
Lebedeva OV, Sidorov PI, Bazhukova TA, Soloviev AG, 
Barve SS, McClain CJ, Cave M. Probiotics restore bowel 
flora and improve liver enzymes in human alcohol-induced 
liver injury: a pilot study. Alcohol 2008; 42: 675-682
33 Forsyth CB, Farhadi A, Jakate SM, Tang Y, Shaikh M, 
Keshavarzian A. Lactobacillus GG treatment ameliorates 
alcohol-induced intestinal oxidative stress, gut leakiness, 
and liver injury in a rat model of alcoholic steatohepatitis. 
Alcohol 2009; 43: 163-172
34 Mutlu E, Keshavarzian A, Engen P, Forsyth CB, Sikaroodi 
M, Gillevet P. Intestinal dysbiosis: a possible mechanism of 
alcohol-induced endotoxemia and alcoholic steatohepatitis 
in rats. Alcohol Clin Exp Res 2009; 33: 1836-1846
35 Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, 
Tuohy KM, Gibson GR, Delzenne NM. Selective increases 
of bifidobacteria in gut microflora improve high-fat-diet-
induced diabetes in mice through a mechanism associated 
with endotoxaemia. Diabetologia 2007; 50: 2374-2383
36 Lata J, Novotný I, Príbramská V, Juránková J, Fric P, Kroupa 
R, Stibůrek O. The effect of probiotics on gut flora, level of 
endotoxin and Child-Pugh score in cirrhotic patients: results 
of a double-blind randomized study. Eur J Gastroenterol 
Hepatol 2007; 19: 1111-1113
37 Guerrero Hernández I, Torre Delgadillo A, Vargas Vorackova 
F, Uribe M. Intestinal flora, probiotics, and cirrhosis. Ann 
Hepatol 2008; 7: 120-124
38 Zhao HY, Wang HJ, Lu Z, Xu SZ. Intestinal microflora in 
patients with liver cirrhosis. Chin J Dig Dis 2004; 5: 64-67
39 Adawi D, Ahrné S, Molin G. Effects of different probiotic 
strains of Lactobacillus and Bifidobacterium on bacterial 
translocation and liver injury in an acute liver injury model. 
Int J Food Microbiol 2001; 70: 213-220
40 Osman N, Adawi D, Ahrné S, Jeppsson B, Molin G. Endotoxin- 
and D-galactosamine-induced liver injury improved by 
the administration of Lactobacillus, Bifidobacterium and 
blueberry. Dig Liver Dis 2007; 39: 849-856
41 Gratz S, Wu QK, El-Nezami H, Juvonen RO, Mykkänen 
H, Turner PC. Lactobacillus rhamnosus strain GG reduces 
aflatoxin B1 transport, metabolism, and toxicity in Caco-2 
Cells. Appl Environ Microbiol 2007; 73: 3958-3964
42 Turner PC, Wu QK, Piekkola S, Gratz S, Mykkänen H, El-
Nezami H. Lactobacillus rhamnosus strain GG restores 
alkaline phosphatase activity in differentiating Caco-2 cells 
dosed with the potent mycotoxin deoxynivalenol. Food 
Chem Toxicol 2008; 46: 2118-2123
43 Zsivkovits M, Fekadu K, Sontag G, Nabinger U, Huber 
WW, Kundi M, Chakraborty A, Foissy H, Knasmüller S. 
Prevention of heterocyclic amine-induced DNA damage 
in colon and liver of rats by different lactobacillus strains. 
Carcinogenesis 2003; 24: 1913-1918
44 Terahara M, Meguro S, Kaneko T. Effects of lactic acid 
bacteria on binding and absorption of mutagenic heterocyclic 
amines. Biosci Biotechnol Biochem 1998; 62: 197-200
45 Gratz S, Täubel M, Juvonen RO, Viluksela M, Turner PC, 
Mykkänen H, El-Nezami H. Lactobacillus rhamnosus strain 
GG modulates intestinal absorption, fecal excretion, and 
toxicity of aflatoxin B(1) in rats. Appl Environ Microbiol 2006; 
72: 7398-7400
46 El-Nezami HS, Polychronaki NN, Ma J, Zhu H, Ling 
W, Salminen EK, Juvonen RO, Salminen SJ, Poussa T, 
Mykkänen HM. Probiotic supplementation reduces a 
biomarker for increased risk of liver cancer in young men 
from Southern China. Am J Clin Nutr 2006; 83: 1199-1203
47 Liong MT. Safety of probiotics: translocation and infection. 
Nutr Rev 2008; 66: 192-202
48 Salminen MK, Tynkkynen S, Rautelin H, Saxelin M, Vaara 
M, Ruutu P, Sarna S, Valtonen V, Järvinen A. Lactobacillus 
bacteremia during a rapid increase in probiotic use of 
Gratz SW et al . Probiotics and liver diseases
410 January 28, 2010|Volume 16|Issue 4|WJG|www.wjgnet.com
Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002; 
35: 1155-1160
49 Dugoua JJ, Machado M, Zhu X, Chen X, Koren G, Einarson 
TR. Probiotic safety in pregnancy: a systematic review 
and meta-analysis of randomized controlled trials of 
Lactobacillus, Bifidobacterium, and Saccharomyces spp. J 
Obstet Gynaecol Can 2009; 31: 542-552
50 Cannon JP, Lee TA, Bolanos JT, Danziger LH. Pathogenic 
relevance of Lactobacillus: a retrospective review of over 
200 cases. Eur J Clin Microbiol Infect Dis 2005; 24: 31-40
51 Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin 
M, Valtonen V, Järvinen A. Lactobacillus bacteremia, 
clinical significance, and patient outcome, with special focus 
on probiotic L. rhamnosus GG. Clin Infect Dis 2004; 38: 62-69
52 Martin FP, Sprenger N, Yap IK, Wang Y, Bibiloni R, Rochat 
F, Rezzi S, Cherbut C, Kochhar S, Lindon JC, Holmes 
E, Nicholson JK. Panorganismal gut microbiome-host 
metabolic crosstalk. J Proteome Res 2009; 8: 2090-2105
53 Martin FP, Wang Y, Sprenger N, Yap IK, Lundstedt T, Lek 
P, Rezzi S, Ramadan Z, van Bladeren P, Fay LB, Kochhar S, 
Lindon JC, Holmes E, Nicholson JK. Probiotic modulation 
of symbiotic gut microbial-host metabolic interactions in a 
humanized microbiome mouse model. Mol Syst Biol 2008; 
4: 157
54 Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, 
Rothwell A, Fearnside J, Tatoud R, Blanc V, Lindon JC, 
Mitchell SC, Holmes E, McCarthy MI, Scott J, Gauguier D, 
Nicholson JK. Metabolic profiling reveals a contribution of 
gut microbiota to fatty liver phenotype in insulin-resistant 
mice. Proc Natl Acad Sci USA 2006; 103: 12511-12516
55 Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou 
H, Zhang Y, Shen J, Pang X, Zhang M, Wei H, Chen Y, 
Lu H, Zuo J, Su M, Qiu Y, Jia W, Xiao C, Smith LM, Yang 
S, Holmes E, Tang H, Zhao G, Nicholson JK, Li L, Zhao 
L. Symbiotic gut microbes modulate human metabolic 
phenotypes. Proc Natl Acad Sci USA 2008; 105: 2117-2122
S- Editor  Tian L    L- Editor  Stewart GJ    E- Editor  Zheng XM
Gratz SW et al . Probiotics and liver diseases
